Finzati - Logo
BIVI logo

BioVie Inc.

BIVI • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$15.76M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.03Healthy liquidity · 3.59Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 26, 2026, 12:17 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$15.76M
52W Range0.82 - 3.79
Beta0.67
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.03
Current Ratio3.59
Quick Ratio3.59
Volume1.01M

Investment DNA

How strong this company looks for long-term investors

41
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Manageable debt level · 0.03Healthy liquidity · 3.59Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 9/18/2020
Industry: Biotechnology
P/B i: 0.00
Debt / Equity i: 0.03
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.03
Current Ratio: 3.59
Quick Ratio: 3.59
Status: Good

Insider Transactions

Recent executive and insider activity

Lang James Paul
Transaction: 01/05/2026
BUY
Change
+90,000
Price
$1.31
Filing
01/09/2026
Type
BUY
Chappell Amy Suzon
Transaction: 01/05/2026
BUY
Change
+57,500
Price
$1.31
Filing
01/09/2026
Type
BUY
Farag Kameel D.
Transaction: 01/05/2026
BUY
Change
+57,500
Price
$1.31
Filing
01/09/2026
Type
BUY